- 专利标题： Inhibition of dendritic cell-driven regulatory T cell activation and potentiation of tumor antigen-specific T cell responses by interleukin-15 and MAP kinase inhibitor
-
申请号： US12286122申请日： 2008-09-27
-
公开(公告)号： US08546137B2公开(公告)日： 2013-10-01
- 发明人: Martin J. Cannon , Kellie L. Kozak , Timothy J. O'Brien
- 申请人： Martin J. Cannon , Kellie L. Kozak , Timothy J. O'Brien
- 申请人地址： US AR Little Rock US MD Bethesda
- 专利权人： The Board of Trustees of the University of Arkansas,National Institutes of Health, US Dept. of Health and Human Services
- 当前专利权人： The Board of Trustees of the University of Arkansas,National Institutes of Health, US Dept. of Health and Human Services
- 当前专利权人地址： US AR Little Rock US MD Bethesda
- 代理商 Hugh McTavish
- 主分类号： C12N5/071
- IPC分类号： C12N5/071 ; C12N5/00 ; C12N5/02
摘要：
The invention involves the discovery that if dendritic cells loaded with a tumor antigen are cultured in interleukin-15 (IL-15), or if T cells activated by the dendritic cells are cultured in IL-15, Treg activity that is specific for the tumor antigen is reduced. This reduction in Treg activity results in an increase in anti-tumor immune response. Another embodiment of the invention involves the discovery that incubating dendritic cells with a MAP kinase inhibitor in combination with IL-15 gives synergistic benefits when the dendritic cells are used to activate T cells. Dendritic cell and T cell compositions incubated with IL-15 or a MAP kinase inhibitor are provided.
公开/授权文献
信息查询
